» Articles » PMID: 33574795

Genetic and Epigenetic Causes of Pituitary Adenomas

Overview
Specialty Endocrinology
Date 2021 Feb 12
PMID 33574795
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

Pituitary adenomas (PAs) can be classified as non-secreting adenomas, somatotroph adenomas, corticotroph adenomas, lactotroph adenomas, and thyrotroph adenomas. Substantial advances have been made in our knowledge of the pathobiology of PAs. To obtain a comprehensive understanding of the molecular biological characteristics of different types of PAs, we reviewed the important advances that have been made involving genetic and epigenetic variation, comprising genetic mutations, chromosome number variations, DNA methylation, microRNA regulation, and transcription factor regulation. Classical tumor predisposition syndromes include multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4) syndromes, Carney complex, and X-LAG syndromes. PAs have also been described in association with succinate dehydrogenase-related familial PA, neurofibromatosis type 1, and von Hippel-Lindau, DICER1, and Lynch syndromes. Patients with aryl hydrocarbon receptor-interacting protein () mutations often present with pituitary gigantism, either in familial or sporadic adenomas. In contrast, guanine nucleotide-binding protein G(s) subunit alpha () and G protein-coupled receptor 101 () mutations can lead to excess growth hormone. Moreover, the deubiquitinase gene , , and mutations are associated with adrenocorticotropic hormone production. In this review, we describe the genetic and epigenetic landscape of PAs and summarize novel insights into the regulation of pituitary tumorigenesis.

Citing Articles

Somatic GNAS mutations in acromegaly: prevalence, clinical features and gender differences.

Yang Y, Yao Y, Deng K, Xing B, Lian W, You H Endocr Connect. 2024; 14(1.

PMID: 39513543 PMC: 11728932. DOI: 10.1530/EC-24-0266.


scRNA sequencing technology for PitNET studies.

Asaad W, Utkina M, Shcherbakova A, Popov S, Melnichenko G, Mokrysheva N Front Endocrinol (Lausanne). 2024; 15:1414223.

PMID: 39114291 PMC: 11303145. DOI: 10.3389/fendo.2024.1414223.


[Unification of pathomorphological examination of patients with neuroendocrine tumors of the pituitary gland. Controversial issues of the new classification].

Pronin V, Antsiferov M, Alekseeva T, Pronin E, Lapshina A, Urusova L Probl Endokrinol (Mosk). 2024; 70(3):31-45.

PMID: 39069771 PMC: 11334236. DOI: 10.14341/probl13376.


Germline Variants in Sporadic Pituitary Adenomas.

Alzahrani A, Bin Nafisah A, Alswailem M, Alghamdi B, Alsaihati B, Aljafar H J Endocr Soc. 2024; 8(6):bvae085.

PMID: 38745824 PMC: 11091836. DOI: 10.1210/jendso/bvae085.


Pathogenesis, clinical features, and treatment of plurihormonal pituitary adenoma.

Cai Y, Liu S, Zhao X, Ren L, Liu X, Gang X Front Neurosci. 2024; 17:1323883.

PMID: 38260014 PMC: 10800528. DOI: 10.3389/fnins.2023.1323883.


References
1.
Ren J, Jian F, Jiang H, Sun Y, Pan S, Gu C . Decreased expression of SFRP2 promotes development of the pituitary corticotroph adenoma by upregulating Wnt signaling. Int J Oncol. 2018; 52(6):1934-1946. PMC: 5919716. DOI: 10.3892/ijo.2018.4355. View

2.
Thakker R . Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res Clin Endocrinol Metab. 2010; 24(3):355-70. DOI: 10.1016/j.beem.2010.07.003. View

3.
Franck S, Gatto F, van der Lely A, Janssen J, Dallenga A, Nagtegaal A . Somatostatin Receptor Expression in GH-Secreting Pituitary Adenomas Treated with Long-Acting Somatostatin Analogues in Combination with Pegvisomant. Neuroendocrinology. 2016; 105(1):44-53. PMC: 5475231. DOI: 10.1159/000448429. View

4.
Hernandez M, Andres-Barquin P, Holt I, Israel M . Cloning of human ENC-1 and evaluation of its expression and regulation in nervous system tumors. Exp Cell Res. 1998; 242(2):470-7. DOI: 10.1006/excr.1998.4109. View

5.
Ostrom Q, Gittleman H, Liao P, Rouse C, Chen Y, Dowling J . CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014; 16 Suppl 4:iv1-63. PMC: 4193675. DOI: 10.1093/neuonc/nou223. View